Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary
24 Juin 2021 - 1:30PM
Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome
editing company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, today announced
the appointment of James Basta, J.D., as Executive Vice President,
General Counsel and Corporate Secretary.
Mr. Basta is coming to Intellia with more than 25 years of
combined in-house corporate and law firm experience, most recently
as Chief Legal Officer at Kura Oncology. Prior to Kura, Mr. Basta
served in various roles in the legal department at Biogen including
as Senior Vice President, Chief Corporation Counsel, where he
managed the legal representation for Biogen’s securities filings,
board of directors, business development, finance and tax,
corporate affairs, employment and information technology. Prior to
joining Biogen in 2006, he was a Partner at Baker &
McKenzie.
Mr. Basta succeeds José Rivera, one of Intellia’s founding
employees in 2014, who has served as Executive Vice President,
General Counsel and Corporate Secretary, since then. Mr. Rivera
will serve as special advisor to Mr. Basta to ensure a smooth
transition and advise on key legal matters.
“We are thrilled to welcome Jim, who brings a wealth of
experience across a diverse range of legal activities including
supporting research and development, business development,
partnering and corporate stewardship. He is a strong addition to
our executive leadership team as we advance our clinical programs
with the goal of developing curative genome editing therapies for
patients across the globe,” said Intellia President and Chief
Executive Officer John Leonard, M.D. “We also thank José for his
leadership and ceaseless devotion to Intellia as we grew from an
idea to a clinical-stage company. He has been an essential partner
to me and the company, and we look forward to continuing to work
with him as he transitions into a new chapter in his life.”
Mr. Basta serves on the Executive Advisory Board of the
Chemistry Life Processes Institute at Northwestern University. He
earned his J.D. from Northwestern University Pritzker School of Law
and his B.A. in economics from Northwestern University.
About Intellia TherapeuticsIntellia
Therapeutics is a leading clinical-stage genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
both producing therapeutics that permanently edit and/or correct
disease-associated genes in the human body with a single
administration, and creating enhanced engineered cells that can
treat oncological and immunological diseases. Intellia’s
combination of deep scientific, technical and clinical development
experience, along with its leading intellectual property portfolio,
puts it in a unique position to unlock broad therapeutic
applications of the CRISPR/Cas9 technology and create new classes
of therapeutic products. Learn more about Intellia and CRISPR/Cas9
at intelliatx.com. Follow us on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements” of
Intellia Therapeutics, Inc. (“Intellia”) within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express
or implied statements regarding Intellia’s ability to advance and
expand the CRISPR/Cas9 technology to develop into human therapeutic
products, as well as our CRISPR/Cas9 intellectual property
portfolio; achieve stable or effective genome editing; the timing
and potential achievement of milestones to advance our pipeline and
grow as a company; and the anticipated contribution of the members
of our board of directors and our executives to our operations and
progress.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to Intellia’s ability to protect and maintain its
intellectual property position; risks related to Intellia’s
relationship with third parties, including its licensors and
licensees; risks related to the ability of its licensors to protect
and maintain their intellectual property position; uncertainties
related to the authorization, initiation and conduct of studies and
other development requirements for its product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed, manufactured and commercialized; the risk
that the results of preclinical studies or clinical studies will
not be predictive of future results in connection with future
studies; the risk that Intellia may not be able to meet or comply
with applicable laws and regulations, including clinical,
manufacturing and commercialization requirements; and the risk that
Intellia’s collaborations with Novartis Institutes for BioMedical
Research, Inc. or Regeneron Pharmaceuticals, Inc. or its other ex
vivo collaborations will not continue or will not be successful.
For a discussion of these and other risks and uncertainties, and
other important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K as well as discussions of
potential risks, uncertainties, and other important factors in
Intellia’s other filings with the Securities and Exchange
Commission (“SEC”). All information in this press release is as of
the date of the release, and Intellia undertakes no duty to update
this information unless required by law.
Intellia Contacts:
Investors:
Lina LiDirectorInvestor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:
Julie Ferguson(Interim) Head of External Affairs &
Communications+1-312-385-0098julie.ferguson@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024